<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="954">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01885871</url>
  </required_header>
  <id_info>
    <org_study_id>C-13-LPS03</org_study_id>
    <secondary_id>C-13-LPS03</secondary_id>
    <nct_id>NCT01885871</nct_id>
  </id_info>
  <brief_title>Laser Removal of Age (Sun) Spots on Hands</brief_title>
  <official_title>Safety and Efficacy of Cutera Picosecond Q-Switched Nd:YAG Laser in the Treatment of Solar Lentigines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cutera Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cutera Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether picosecond laser is effective in the
      treatment of age (sun) spots.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of Cutera Picosecond
      Q-Switched Nd:YAG 1064 and/or 532 nm laser in the treatment of benign pigmented lesions on
      the hands.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">August 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Median VAS Improvement Score as Assessed by Blinded Physician Reviewers</measure>
    <time_frame>12 weeks post- final treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement (clearing) in solar lentigines as assessed by blinded physician reviewers using a VAS 4 point scale 0-3 where 0=no change and 3=Very much improved.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants With Improvement Score &gt;/=1</measure>
    <time_frame>12 weeks post- final treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Improvement (clearing) in solar lentigines as assessed by participant using a 4-point VAS 0-3 scale where 0=no change and 3=very much improved. Scores &gt;/=1 indicate improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Participants Satisfied With Improvement (Clearing) in Solar Lentigines</measure>
    <time_frame>12 weeks post- final treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Level of Satisfaction with Improvement (clearing) in solar lentigines as assessed by participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Pain Score Associated With Laser Treatment</measure>
    <time_frame>During treatment</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Subjects graded the level of pain associated with laser treatment using a 0-10 scale where 0=no pain and 10=worse possible pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Subjects With Post-treatment Adverse Event</measure>
    <time_frame>During study duration 0-6 months.</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Solar Lentigines</condition>
  <arm_group>
    <arm_group_label>Picosecond QS Nd:YAG Laser</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laser Treatment with Investigational Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Picosecond QS Nd:YAG Laser</intervention_name>
    <description>Up to 2 laser treatments delivered 6 weeks apart</description>
    <arm_group_label>Picosecond QS Nd:YAG Laser</arm_group_label>
    <other_name>Cutera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Females or Males, 18 to 60 years of age (inclusive).

          -  Fitzpatrick Skin Type I - III (Appendix 2).

          -  Clinical diagnosis of benign solar lentigines of the hands.

          -  Presence of at least 5 lesions in the treatment area in diameters ranging from 1 to 8
             mm.

          -  Has not used any prescription or over the counter topical creams (e.g., hydroquinone,
             and/or retinoids and/or corticosteroids) used in the treatment of pigmentation in the
             treatment area within the last 4 weeks.

          -  Willing to refrain from using any prescription or over the counter topical creams
             used for the treatment of pigmentation (e.g., hydroquinone, and/or retinoids and/or
             corticosteroids) in the treatment area during the study period.

          -  Must be able to read, understand and sign the Informed Consent Form.

          -  Willing and able to adhere to the treatment and follow-up schedule and before and
             after treatment care instructions.

          -  Willing to protect and/or have very limited sun exposure and use an approved
             sunscreen of SPF 50 or higher in the treatment area starting up to 4 weeks before the
             treatment, every day for the duration of the study, including the follow-up period

          -  Willing to have digital photographs taken of the treatment area

          -  Agree not to undergo any other procedure(s) for the treatment of solar lentigines
             during the study.

          -  Post-menopausal or surgically sterilized, or using a medically acceptable form of
             birth control at last 3 months prior to enrollment and during the entire course of
             the study.

        Exclusion Criteria:

          -  Participation in a study of another device of drug within 6 months prior to
             enrollment or during the study.

          -  Prior treatment of solar lentigines of the hands, e.g., with Q-Switched laser, IPL,
             Chemical peel, cryotherapy within 6 months of study participation.

          -  Having pre-malignant or malignant lesions (e.g., pigmented actinic keratosis, lentigo
             maligna [12], lentigo maligna melanoma), or history of a pre-malignant or malignant
             lesion in the treatment area.

          -  Subject shows signs of actinic bronzing or recent tanning in the treatment area, and
             unable/unlikely to refrain from tanning during the study.

          -  Skin abnormalities in the treatment area, e.g., cuts, scrapes, wounds, scars, large
             moles.

          -  Pregnant and/or breastfeeding.

          -  Having an infection, dermatitis or a rash in the treatment area.

          -  Significant concurrent illness, such as diabetes mellitus or cardiovascular disease,
             e.g., uncontrolled hypertension

          -  Suffering from coagulation disorders or taking prescription anticoagulation
             medications.

          -  History of keloid scarring, hypertrophic scarring or of abnormal wound healing.

          -  History of immunosuppression/immune deficiency disorders or currently using
             immunosuppression medications.

          -  History of vitiligo or psoriasis.

          -  History of connective tissue disease, such as systemic lupus erythematosus or
             scleroderma.

          -  History of seizure disorders due to light.

          -  Any use of medication that is known to increase sensitivity to light, such as
             tetracycline.

          -  History of radiation to the treatment area or undergoing systemic chemotherapy for
             the treatment of cancer.

          -  History of pigmentary disorders, particularly tendency for hyper- or
             hypo-pigmentation.

          -  Anytime in life, having have used gold therapy (gold salts) for disorders such as
             rheumatologic disease or lupus.

          -  Current smoker or history of smoking within 2 years of study participation.

          -  As per the Investigator's discretion, any physical or mental condition which might
             make it unsafe for the subject to participate in this study.

          -  History of allergy to topical antibiotics.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lourdes Moldre, NP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cutera Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cutera Research Center</name>
      <address>
        <city>Brisbane</city>
        <state>California</state>
        <zip>94005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2015</verification_date>
  <lastchanged_date>October 9, 2015</lastchanged_date>
  <firstreceived_date>June 21, 2013</firstreceived_date>
  <firstreceived_results_date>March 3, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sun</keyword>
  <keyword>Age</keyword>
  <keyword>Spot</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lentigo</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Picosecond Q-Switched Nd:YAG 1064/532 nm Laser</title>
          <description>Picosecond Q-Switched Nd:YAG 1064/532 nm Laser: Up to 2 laser treatments delivered 6 weeks apart</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Picosecond Q-Switched Nd:YAG 1064/532 nm Laser</title>
          <description>Picosecond Q-Switched Nd:YAG 1064/532 nm Laser: Up to 2 laser treatments delivered 6 weeks apart</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="52" lower_limit="41" upper_limit="67"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="19"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or Other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black or African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>More than one race</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Not Hispanic or Latino</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="18"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Unknown or Not Reported</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Median VAS Improvement Score as Assessed by Blinded Physician Reviewers</title>
        <description>Improvement (clearing) in solar lentigines as assessed by blinded physician reviewers using a VAS 4 point scale 0-3 where 0=no change and 3=Very much improved.</description>
        <time_frame>12 weeks post- final treatment</time_frame>
        <safety_issue>No</safety_issue>
        <population>Based on blinded photographic assessments of 20 subjects. Scores &gt;/=1 indicate clearing.</population>
        <group_list>
          <group group_id="O1">
            <title>Picosecond Q-Switched Nd:YAG 1064/532 nm Laser</title>
            <description>Picosecond Q-Switched Nd:YAG 1064/532 nm Laser: Up to 2 laser treatments delivered 6 weeks apart</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Median VAS Improvement Score as Assessed by Blinded Physician Reviewers</title>
            <description>Improvement (clearing) in solar lentigines as assessed by blinded physician reviewers using a VAS 4 point scale 0-3 where 0=no change and 3=Very much improved.</description>
            <units>units on a scale</units>
            <param>Median</param>
            <dispersion>95% Confidence Interval</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="1.5" lower_limit="1.25" upper_limit="2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.0001</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants With Improvement Score &gt;/=1</title>
        <description>Improvement (clearing) in solar lentigines as assessed by participant using a 4-point VAS 0-3 scale where 0=no change and 3=very much improved. Scores &gt;/=1 indicate improvement.</description>
        <time_frame>12 weeks post- final treatment</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Picosecond Q-Switched Nd:YAG 1064/532 nm Laser</title>
            <description>Picosecond Q-Switched Nd:YAG 1064/532 nm Laser: Up to 2 laser treatments delivered 6 weeks apart</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Participants With Improvement Score &gt;/=1</title>
            <description>Improvement (clearing) in solar lentigines as assessed by participant using a 4-point VAS 0-3 scale where 0=no change and 3=very much improved. Scores &gt;/=1 indicate improvement.</description>
            <units>percent of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="90"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Participants Satisfied With Improvement (Clearing) in Solar Lentigines</title>
        <description>Level of Satisfaction with Improvement (clearing) in solar lentigines as assessed by participants.</description>
        <time_frame>12 weeks post- final treatment</time_frame>
        <safety_issue>No</safety_issue>
        <population>Based on subject questionnaires, 90% of subjects reported improvement (clearing) in benign pigmented lesions at 12 weeks post- final treatment. Scores &gt;/=1 indicate improvement.</population>
        <group_list>
          <group group_id="O1">
            <title>Picosecond Q-Switched Nd:YAG 1064/532 nm Laser</title>
            <description>Picosecond Q-Switched Nd:YAG 1064/532 nm Laser: Up to 2 laser treatments delivered 6 weeks apart</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Participants Satisfied With Improvement (Clearing) in Solar Lentigines</title>
            <description>Level of Satisfaction with Improvement (clearing) in solar lentigines as assessed by participants.</description>
            <units>percent of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="95"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Pain Score Associated With Laser Treatment</title>
        <description>Subjects graded the level of pain associated with laser treatment using a 0-10 scale where 0=no pain and 10=worse possible pain.</description>
        <time_frame>During treatment</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Picosecond Q-Switched Nd:YAG 1064/532 nm Laser</title>
            <description>Picosecond Q-Switched Nd:YAG 1064/532 nm Laser: Up to 2 laser treatments delivered 6 weeks apart</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Mean Pain Score Associated With Laser Treatment</title>
            <description>Subjects graded the level of pain associated with laser treatment using a 0-10 scale where 0=no pain and 10=worse possible pain.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Full Range</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="2.0" lower_limit="1.0" upper_limit="5.0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Subjects With Post-treatment Adverse Event</title>
        <time_frame>During study duration 0-6 months.</time_frame>
        <safety_issue>Yes</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Picosecond Q-Switched Nd:YAG 1064/532 nm Laser</title>
            <description>Picosecond Q-Switched Nd:YAG 1064/532 nm Laser: Up to 2 laser treatments delivered 6 weeks apart</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="20"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Subjects With Post-treatment Adverse Event</title>
            <units>percent of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Erythema (redness)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Edema (swelling)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Crusting (scabbing)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Purpura (bruising)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="65"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Blisters</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Event Data was collected immediately post treatment, 3 days and 14 days after treatment as well as 6, 12, and 24 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Picosecond Q-Switched Nd:YAG 1064/532 nm Laser</title>
          <description>Picosecond Q-Switched Nd:YAG 1064/532 nm Laser: Up to 2 laser treatments delivered 6 weeks apart</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Edema</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Edema (swelling)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title vocab="Erythema">Erythema (Redness)</sub_title>
                <counts group_id="E1" events="20" subjects_affected="20" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title vocab="Purpura">Purpura (Bruising)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title vocab="Blisters">Blisters</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Research Department</name_or_title>
      <organization>Cutera, Inc</organization>
      <phone>1-888-428-8372</phone>
      <email>gweiss@cutera.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
